ImmunityBio, Inc. IBRX Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- ImmunityBio, Inc. (IBRX) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $79.38M in Q1 2026.
- How has ImmunityBio, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- ImmunityBio, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale increased by 1383.8% year-over-year, from $5.35M to $79.38M.
- What is the long-term trend for ImmunityBio, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 3 years (2021 to 2024), ImmunityBio, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 27.2% compound annual growth rate (CAGR), from $56.17M to $115.59M.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.